Aspire launches direct-to-consumer website for sublingual caffeine product

ESTERO, FL - Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP), a micro-cap company with a market value of $20.93 million, has launched a new e-commerce platform, buzzbomb.buzz, featuring its sublingual pre-workout supplement BUZZ BOMB, according to a press release statement issued Thursday. According to InvestingPro analysis, the company currently shows weak financial health metrics.

The product delivers 50mg of caffeine through small packets placed under the tongue, designed for absorption without mixing with water. The company states the supplement is intended to provide rapid energy for athletes and fitness enthusiasts.

The e-commerce site offers BUZZ BOMB in four flavors: Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha. Customers can purchase sample packs or 30-packs in various configurations.

"This launch enables us to offer our advanced sublingual pre-workout supplement directly to customers across the nation and at a competitive price," said Kraig Higginson, Interim Chief Executive Officer of Aspire.

The company claims its patent-pending delivery technology allows for faster absorption compared to traditional pre-workout supplements that require mixing with water and consumption before exercise.

Aspire Biopharma, headquartered in Florida, reports that early registrants on the new website will receive access to special pricing, free shipping offers, and other promotions.

The company also mentioned plans to showcase the product at two fitness conventions in early August as part of its marketing strategy.

In other recent news, Aspire Biopharma Holdings has announced the launch of its new sublingual pre-workout supplement, BUZZ BOMB, at major fitness conventions in early August. The product will be showcased at FitCon in Salt Lake City and FitExpo in Anaheim. Meanwhile, the company has relocated its headquarters to Estero, Florida, as approved by its Board of Directors. In leadership changes, Michael C. Howe has been appointed as the new CEO, bringing over four decades of experience in consumer and healthcare sectors. This transition comes as Aspire Biopharma prepares for significant milestones, including a clinical trial and a product launch in 2025. Additionally, Aspire Biopharma has settled with Cobra Alternative Capital Strategies LLC and Blackstone Capital Advisors, amending terms of existing loan agreements and extending loan maturities. The settlement includes issuing 625,000 shares of common stock to Blackstone Capital Advisors, with a registration statement to be filed by mid-May. Lock-up restrictions on shares held by lenders will also be lifted, allowing transfers to the Direct Registration System.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.